Searched for
SYNGENE GROWTH
Ahead of Market: 10 things that will decide stock market action on FridayIndian equities extended gains after the US Federal Reserve kept rates unchanged, with Sensex rising 274 points and Nifty closing above 24,...- Delayed monsoon may weigh on auto demand, but long-term outlook stays strong: Aditya ShahA delayed monsoon poses a temporary challenge to rural auto demand, particularly for tractors and two-wheelers, but the sector's long-term ...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- Syngene International shares slump 10% after Q4 profit dips despite revenue growthSyngene International's shares plummeted 10% following a reported 3% year-on-year decline in consolidated net profit for Q4 FY25, despite a...
- Syngene's MD & CEO Jonathan Hunt steps down, Peter Bains named as new CEOJonathan Hunt has stepped down as the managing director and CEO of Syngene International, with Peter Bains appointed as the CEO Designate e...
- Syngene Q3 Results: Net profit rose 18% YoY to Rs 131 croreSyngene reported 18% YoY growth in Q3FY25 net profit. Revenue rose 11% YoY. EBITDA margin improved to 31.4%. Company expects single-digit r...
- Syngene Q4 Results: Net profit rises 6% to Rs 189 crore, revenue drops 8%The earnings before interest, tax, depreciation and ammortisation dropped 1% YoY to Rs. 333 crore in Q4FY24. The EBITDA margin rose 300 bas...
- Syngene can put on muscle as global pharma companies increase R&D spendingSyngene is a fully integrated CRAMS company and Biocon has around 70% stake in it. Syngene also has a wholly-owned subsidiary in the US.
- Seeing good demand for biologics manufacturing: Syngene CEO Jonathan HuntIn an interview to ET, Jonathan Hunt, CEO and MD of Syngene said the company has spare capacity and is also investing on expansion of micro...
- Discovery, development, dedicated centres and manufacturing biz contribute to Syngene growth: Jonathan Hunt“$100-120 million capex will be for a little bit of catch-up and the rest of it will be investment in the future growth of the company.”
- Jefferies maintains 'buy' on Syngene International, target price of Rs 350Shares of Syngene International ended up 1.7% at Rs 298.65 on Wednesday.
- Add Syngene International, target Rs 650: Yes SecuritiesAdd Syngene International at a price target of Rs 650.
- Syngene appoints Jonathan Hunt as CEO-designateHunt will take charge after the retirement of current CEO Peter Bains in March, Syngene International said in a regulatory filing.
- Syngene International makes stellar debut, ends day up 24% over issue priceIt hit an intraday high of Rs 318.20 over its issue price, before settling the day at Rs 310.40, up 24.16 per cent on the BSE.
- Is it time to book profits on Biocon counter post Syngene listing?Biocon has gained nearly 9 per cent in the past six months, compared to a 2 per cent fall in the BSE benchmark Sensex.
- Syngene's valuations are fair, investors need to invest in its growth story: Kiran Mazumdar-ShawIn an interview with ET Now, Kiran Mazumdar-Shaw, CMD, Biocon, talks about the Syngene IPO and the growth prospects involved.
- Top brokers recommend 'subscribe' to Syngene International IPO; here's whyLong-term investors should 'subscribe' to Syngene IPO which opens for subscription today, various brokerages said in a report.
- GEPL Capital recommends 'subscribe' to Syngene International IPOSyngene International Ltd, a subsidiary of leading pharma major Biocon Ltd and India’s leading CRO, is planning to raise Rs 550 crore from ...
- Syngene valuation justified by high growth prospectsPremium valuation seems justified given the good track record in performance, high quality of earnings and growth potential.
Load More
